Search

Background Chagas disease (CD) is a neglected tropical disease, endemic in Latin America, but due to migration and environmental changes it has become a global public health issue. Objectives To assess the global prevalence and disability-adjusted life years due to CD using findings from the Global Burden of Disease Study 2019. Methods The Global Burden of Disease data was obtained from the Global Burden of Disease Collaborative Network; results were provided by the Institute for Health Metrics and Evaluation. The prevalence and disability-adjusted life-years (DALYs) were described at a global, regional, and national level, including data from 1990 to 2019. Results Globally, CD prevalence decreased by 11.3% during the study period, from 7,292,889 cases estimated in 1990 to 6,469,283 in 2019. Moreover, the global DALY rate of CD decreased by 23.7% during the evaluated period, from 360,872 in 1990 to 275,377 in 2019. In addition, significant differences in the burden by sex, being men the most affected, age, with the elderly having the highest burden of the disease, and sociodemographic index (SDI), with countries with the lowest SDI values having the highest prevalence of the disease, were observed. Finally, the prevalence trends have followed different patterns according to the region, with a sustained decrease in Latin America, compared to an increasing trend in North America and Europe until 2010. Conclusion The global burden of CD has changed in recent decades, with a sustained decline in the number of cases. Although the majority of cases remain concentrated in Latin America, the increase observed in countries in North America and Europe highlights the importance of screening at-risk populations and raising awareness of this neglected tropical disease.

Background: In the last two decades, several Latin American countries have experienced multiple outbreaks of oral Chagas disease. The study: Retrospective study analyzing an outbreak of acute oral Chagas disease in Sucre, Colombia during December-January 2020. The cases were confirmed by different diagnostic methods. Finding: During two weeks, 16 cases were confirmed, where the mean age was 14 years and 12 were male. Of the total, 14 patients were hospitalized and 2 died. Clinical manifestations include: fever, facial edema, hepatosplenomegaly, In 13 of the patients Trypanosoma cruzi trypomastigotes were observed in the thin and thick smears. Oral transmission is established as the most likely route in 14 of the patients. Conclusions: Acute orally transmitted Chagas disease can be life-threatening or even fatal, therefore, it is urgent to improve epidemiological control measures at the national level and in other Latin American countries. Introducción: En las dos últimas décadas, varios países de América Latina han experimentado múltiples brotes de la enfermedad de Chagas oral. El estudio: Estudio retrospectivo que analiza un brote de enfermedad de Chagas oral aguda en Sucre, Colombia durante diciembre-enero de 2020. Los casos fueron confirmados por diferentes métodos diagnósticos. Hallazgos: Durante dos semanas se confirmaron 16 casos, donde la edad media fue de 14 años. Del total, 14 pacientes fueron hospitalizados y 2 fallecieron. Las manifestaciones clínicas incluyeron: fiebre, edema facial, hepatoesplenomegalia. En 13 de los pacientes se observaron tripomastigotes de Trypanosoma cruzi en los frotis fino y grueso. La transmisión oral se estableció como la vía más probable. Conclusiones: La enfermedad de Chagas aguda transmitida por vía oral puede poner en peligro la vida o incluso ser mortal, por tanto, es urgente mejorar las medidas de control epidemiológico a nivel nacional y en otros países de América Latina.

Resumen Introducción La enfermedad por coronavirus 2019 (COVID-19) puede predisponer a tromboembolia venosa o trombosis arterial debido a una respuesta inflamatoria aumentada, hipoxia, inmovilización y coagulación intravascular diseminada; hasta en un 20 a 50% de pacientes hospitalizados con COVID-19 tienen alteraciones hematológicas relacionadas con coagulopatía (dímero D elevado, tiempo de protrombina prolongado, trombocitopenia y/o fibrinógeno bajo). Evaluaciones post mortem evidencian depósitos trombóticos microvasculares típicos, ricos en plaquetas en vasos pequeños de pulmones y otros órganos. Objetivo Brindar una aproximación práctica y actualizada en el manejo del paciente con riesgo elevado o que presentan eventos tromboembólicos en el marco de la actual pandemia por COVID-19. Material y métodos: Se realizó una revisión narrativa que incluyó estudios observacionales descriptivos. Se efectuó una búsqueda de la literatura de evidencia médica en diferentes buscadores como Science Direct y PubMed, usando las palabras claves “thromboprophylaxis”, “anticoagulation”, “thrombosis”, “anticoagulant”, “COVID-19”, “SARS-CoV-2”, “coronavirus”. Posteriormente se escribieron las recomendaciones generales referentes al tema. Conclusiones Existen diferentes formas en las que la pandemia por COVID-19 puede predisponer al desarrollo de enfermedades trombóticas o tromboembólicas, el efecto directo o indirecto de este virus relacionado con la tormenta de citocinas que precipita el inicio del síndrome de respuesta inflamatoria sistémica y predispone al desarrollo de eventos trombóticos; también las intervenciones disponibles pueden tener interacciones farmacológicas con antiagregantes y/o anticoagulantes. Abstract Introduction Coronavirus 19 infection can predispose to VTE or arterial thrombosis due to a heightened inflammatory response, hypoxia, immobility and DIC. Up to 20-50% of hospitalized patients with COVID-19 have hematological disorders related to coagulopathies (elevated D-dimer, prolonged PT, thrombocytopenia and/or low fibrinogen). Post-mortem examinations show typical platelet-rich microvascular thrombotic deposits in the small vessels of the lungs and other organs. Objective To provide a practical, updated approach to the treatment of patients at high risk for or with ongoing thromboembolic events in the current COVID-19 pandemic setting. Material and methods A narrative review was performed including descriptive observational studies. A search of the medical evidence literature was carried out in different search engines such as ScienceDirect and PubMed, using the following key words: “thromboprophylaxis”, “anticoagulation”, “thrombosis”, “anticoagulant”, “COVID-19”, “SARS-CoV-2”, and “coronavirus”, and general recommendations on the topic were subsequently composed. Conclusions The are various ways in which the COVID-19 pandemic may predispose to the development of thrombotic or thromboembolic diseases. The virus may have a direct or indirect effect related to the cytokine storm which triggers the onset of systemic inflammatory response syndrome and predisposes to the development of thrombotic events. The available interventions may also have pharmacological interactions with antiplatelet drugs and/or anticoagulants.

Resumen El registro RECOLFACA es la primera aproximación que se realiza en Colombia sobre el perfil clínico y demográfico de los pacientes con falla cardiaca, e incluye instituciones de gran parte del territorio nacional. Esta información es de gran relevancia ya que permitirá caracterizar la población y servir como base para diseñar políticas públicas que ofrezcan una mejor atención en salud a esta población. Este importante proyecto epidemiológico, llevado a cabo por el Capítulo de Falla Cardíaca, Trasplantes e Hipertensión Pulmonar de la Sociedad Colombiana de Cardiología y Cirugía Cardiovascular, es pionero en la evaluación de las enfermedades cardiovasculares en Colombia y, adicionalmente, servirá como modelo para la evaluación de otras enfermedades. Abstract The RECOLFACA registry is Colombia’s first approach to describing the clinical and demographic profile of patients with heart failure, which includes institutions throughout much of the country. This information is of great importance as it will characterize the population and serve as the basis for designing public policies which will provide better health care to this population. This important epidemiological project, carried out by the Heart Failure, Transplants and Pulmonary Hypertension Chapter of the Sociedad Colombiana de Cardiología y Cirugía Cardiovascular [Colombian Society of Cardiology and Cardiovascular Surgery] is a pioneer in evaluating cardiovascular diseases in Colombia, and will also serve as a model for evaluating other diseases.

Introduction: Although the Minnesota Living with Heart Failure Questionnaire (MLHF-Q) is one of the most widely used tools to assess Health-Related Quality of Life (HRQoL) in patients with chronic heart failure (CHF), it has not been validated in Latin American Spanish-speaking populations. Objective: We evaluated internal consistency and construct validity of the MLHF-Q in patients with CHF from Colombia. Methods: The Spanish version of the MLHF-Q was given to 200 patients. Cronbach's alpha was used to evaluate internal consistency. Confirmatory factorial Principal Component Analysis (PCA) and Rasch analysis were used to evaluate construct validity. The discriminative capacity was measured using the Mann-Whitney U test. Results: Median age was 64 years, 63% of the patients included in the study were men, and 79.5% had a left ventricular ejection fraction (LVEF) ≤ 45%. The median of the total score of HRQoL was 40 points (Q1=20; Q3=55), physical dimension 11 points (Q1=4; Q3=23) and emotional dimension 7 points (Q1=3; Q3=13). Global internal consistency of MLHF-Q was 0.91 (95% CI 0. 89 - 0.93). In the PCA, the three dimensions explained 47.7% and 54.0% in Rasch analysis, in which five items presented misfit. Worse HRQoL was observed among women than men in the emotional dimension (p=0.047). Discriminative capacity for the overall score of the MLHF-Q and their subscales was observed in age and New York Heart Association (NYHA) functional class (p

Resumen Las miocardiopatías son trastornos intrínsecos del músculo cardíaco. Presentan fenotipos diferenciales que determinan su clasificación; estos son: dilatada, hipertrófica, restrictiva, displasia arritmogénica del ventrículo derecho y no clasificadas. Las miocardiopatías restrictivas se caracterizan por ventrículos de tamaño normal, con grosores de pared normales o ligeramente aumentados, paredes rígidas, disfunción diastólica severa y llenado restrictivo con presiones elevadas. Una de las formas más comunes de miocardiopatía restrictiva es la fibrosis endomiocárdica la cual es endémica en algunas zonas tropicales especialmente en África (países de bajos ingresos), pero en nuestro medio hay pocos reportes de aparición. Su etiología es desconocida, aunque existen diversos mecanismos que han sido involucrados en su fisiopatología. Su diagnóstico se basa en estudios imagenológicos (ecocardiograma transtorácico y resonancia magnética nuclear cardíaca). El pronóstico es muy pobre, y usualmente se diagnostica en etapas muy avanzadas de la enfermedad. Se describe el caso de una paciente femenina, adulta media, que debutó con cardiopatía restrictiva, cuyo diagnóstico final fue fibrosis endomiocárdica. Abstract Cardiomyopathies are intrinsic conditions of the cardiac muscle. They present differential phenotypes that determine their classification. These are: dilated, hypertrophic, restrictive, arrhythmogenic right ventricular and unclassified. Restrictive cardiomyopathies are characterised by larger than normal ventricles with normal or slightly enlarged thickness of the walls, rigid walls, severe diastolic dysfunction and restrictive filling with high pressures. One of the most common restrictive cardiomyopathies is endomyocardial fibrosis, which is endemic to some tropical areas, especially Africa (low income countries), but there are few reports of its occurrence in our environment. Its aetiology is unknown, but there are several mechanisms that have been involved in its pathophysiology. Its diagnosis is based in imaging studies (transthoracic echocardiogram, cardiac nuclear magnetic resonance). Prognosis is very poor, and it is usually diagnoses in the latest stages of the disease. The case of a female, average adult patient that debuted with restrictive cardiomyopathy with a final diagnosis of endomyocardial fibrosis is described.

ResumenLas miocardiopatías son trastornos intrínsecos del músculo cardíaco. Presentan fenotipos diferenciales que determinan su clasificación; estos son: dilatada, hipertrófica, restrictiva, displasia arritmogénica del ventrículo derecho y no clasificadas. Las miocardiopatías restrictivas se caracterizan por ventrículos de tamaño normal, con grosores de pared normales o ligeramente aumentados, paredes rígidas, disfunción diastólica severa y llenado restrictivo con presiones elevadas.Una de las formas más comunes de miocardiopatía restrictiva es la fibrosis endomiocárdica la cual es endémica en algunas zonas tropicales especialmente en África (países de bajos ingresos), pero en nuestro medio hay pocos reportes de aparición. Su etiología es desconocida, aunque existen diversos mecanismos que han sido involucrados en su fisiopatología. Su diagnóstico se basa en estudios imagenológicos (ecocardiograma transtorácico y resonancia magnética nuclear cardíaca). El pronóstico es muy pobre, y usualmente se diagnostica en etapas muy avanzadas de la enfermedad. Se describe el caso de una paciente femenina, adulta media, que debutó con cardiopatía restrictiva, cuyo diagnóstico final fue fibrosis endomiocárdica.AbstractCardiomyopathies are intrinsic conditions of the cardiac muscle. They present differential phenotypes that determine their classification. These are: dilated, hypertrophic, restrictive, arrhythmogenic right ventricular and unclassified. Restrictive cardiomyopathies are characterised by larger than normal ventricles with normal or slightly enlarged thickness of the walls, rigid walls, severe diastolic dysfunction and restrictive filling with high pressures.One of the most common restrictive cardiomyopathies is endomyocardial fibrosis, which is endemic to some tropical areas, especially Africa (low income countries), but there are few reports of its occurrence in our environment. Its aetiology is unknown, but there are several mechanisms that have been involved in its pathophysiology. Its diagnosis is based in imaging studies (transthoracic echocardiogram, cardiac nuclear magnetic resonance). Prognosis is very poor, and it is usually diagnoses in the latest stages of the disease. The case of a female, average adult patient that debuted with restrictive cardiomyopathy with a final diagnosis of endomyocardial fibrosis is described.